Arkolith/Insider Trading/MBX/Form 4

Hawryluk P. Kent

President & CEO, DirectorMBX Biosciences, Inc. (MBX) · full profile →Form 4 · filed Oct 28, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 24, 2025Option exercise(M)183K$3.25$594K664K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 24, 2025Option exercise(M)183K—$0130K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-252404) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML